Medlab Clinical raises $15 million and Leading Executive Joins Board

Date:  2021-03-19
Author:   Medlab
Medlab Clinical Raises Cash for phase 3 clinical trial and Leading Novartis Executive Joins Board

Medlab Clinical successfully raised $15 million via a two-tranche placement. The money will go towards funding a pivotal Phase III clinical trial in Australia, the USA and the UK to investigate the efficacy of Medlab’s non-opioid analgesic drug candidate delivered via NanoCelle® for the treatment of cancer-induced bone pain (bone metastases). NanoCelle® is Medlab’s proprietary drug delivery platform (submicron particle technology).

Medlab has also enhanced its board capability with the appointment of Mrs Cheryl Maley as an Independent Non-Executive Director of the company, effective 19 March 2021. Mrs Maley is currently a Managing Director of Oncology for global healthcare company Novartis (Australia and New Zealand), with over 20 years in roles across Sales, Marketing, Business Development, Commercial Excellence, Patient Access and General Management.

Read about our market release available at SmallCaps

Our recent ASX announcements can be found here


Tell us what you think login to share your thoughts.


Medlab Author
Medlab Author

Medlab in-house Editor.